Emerging research has shed new light on the etiology of sepsis among adults living with HIV in East Africa, revealing tuberculosis (TB) as a previously underestimated but dominant contributor to fatal sepsis cases. Tuberculosis, caused by the bacterium Mycobacterium tuberculosis (Mtb), is a chronic infectious disease primarily affecting the lungs but capable of systemic dissemination, particularly in immunocompromised individuals. A recently published comprehensive study delved into the incidence of Mtb in patients with sepsis co-infected with HIV, unearthing pivotal insights with direct clinical implications.

The research originated from a collaborative effort involving eminent institutions such as Tulane University, University of Virginia, Mbarara University in Uganda, and Tanzania’s Kibong’oto Infectious Diseases Hospital. These institutions pooled resources and expertise to conduct both an observational study and a Phase 3 randomized clinical trial, named the ATLAS study, designed to evaluate the impact of early initiation of TB treatment on sepsis-related mortality in HIV-positive patients.

Traditional sepsis management has relied heavily on diagnostic confirmation before commencing targeted therapy for coexisting infections. However, this study challenges that paradigm by demonstrating that immediate administration of anti-TB therapy, even before establishing a definitive TB diagnosis, can substantially reduce mortality rates. The critical finding from the ATLAS trial was a remarkable 23% reduction in deaths among HIV-infected sepsis patients who received prompt anti-TB drugs, compared to those who had treatment delayed until TB confirmation. This underlines that early therapeutic intervention can save one in every four patients afflicted by this deadly synergy.

Several factors contribute to the under-recognition of TB as a causative agent in sepsis, particularly in resource-constrained settings. Diagnostic tools currently available have limited sensitivity in immunosuppressed populations because sputum samples—the standard for detecting pulmonary TB—are often difficult to obtain or yield false negatives. Moreover, the disseminated nature of TB in these patients causes bloodstream infections that escape detection by routine urine and sputum examinations. The study highlighted that combined urine and sputum testing failed to identify 32% of Mtb bloodstream infections, spotlighting a significant gap in current diagnostic algorithms.

Delving deeper into pathogen prevalence, the research revealed that Mycobacterium tuberculosis was the most frequently detected pathogen in HIV-associated sepsis, present in over half of the cases analyzed. This prevalence starkly underscores the necessity for clinicians in high-burden regions to reconsider diagnostic and treatment strategies. Standard sepsis protocols generally prioritize broad-spectrum antibiotics targeting common bacterial pathogens, yet tuberculosis requires a specific anti-mycobacterial regimen—a discrepancy that can result in missed therapeutic windows and worsened patient outcomes.

Analysis of the ATLAS trial data pointed additionally to dosage considerations. While early treatment yielded clear survival benefits, administering a higher initial dose of anti-TB medication did not translate into further mortality reduction. This suggests that timely initiation at standard doses is critical, but dose escalation alone does not confer additional benefits and could potentially increase adverse effects or resistance risks.

The implications of these findings are multifold. Firstly, they advocate for a paradigm shift in sepsis management in regions where TB and HIV co-infection are endemic. Empirical anti-TB therapy initiation in HIV-positive patients presenting with sepsis symptoms may substantially reduce lethality, challenging global sepsis treatment guidelines to incorporate this approach. Secondly, improving diagnostic techniques is imperative: more sensitive, rapid, and accessible tools are essential to detect Mtb infections early and accurately, guiding appropriate treatment.

This body of research exemplifies the interconnectedness of infectious diseases and the importance of integrated clinical approaches. HIV’s immunosuppressive effects facilitate the systemic spread of TB, transforming a primarily pulmonary infection into a disseminated sepsis driver. Awareness of this relationship among clinicians can foster earlier suspicion and proactive management, vital in reducing the staggering mortality rates.

Furthermore, this work spotlights the broader context of global health disparities. The disproportionate sepsis mortality in Africa reflects gaps in diagnostic infrastructure, access to timely treatments, and healthcare resource allocation. Addressing these systemic issues alongside novel clinical insights is key to improving outcomes for millions who remain vulnerable.

Dr. Eva Otoupalova, Assistant Professor of Pulmonary and Critical Care Medicine at Tulane University School of Medicine, who co-led the study and authored the ATLAS trial, emphasized the transformative potential of early anti-TB intervention. Her commentary underscores the necessity of rethinking clinical algorithms in high-burden settings, suggesting that treatment protocols should adapt to nuanced epidemiological realities rather than adhere strictly to traditional diagnostic confirmation models.

In conclusion, the convergence of sophisticated clinical trials and observational investigations elucidates tuberculosis not merely as a chronic infectious disease but as a critical factor fueling sepsis mortality among individuals with HIV in East Africa. The findings demand urgent attention from the global medical community to revise sepsis management, enhance diagnostic capacities, and allocate resources strategically to save countless lives currently lost to this deadly combination.

Subject of Research: Infectious disease pathology focusing on the etiology and treatment of sepsis in HIV-infected adults in East Africa.

Article Title: Aetiology of sepsis in adults living with HIV in East Africa: a secondary analysis of an open-label, multicentre, randomised, controlled phase 3 trial.

News Publication Date: 27 January 2026.

Web References:

• Lancet E-Clinical Medicine Study
• ATLAS Trial Publication in Lancet Infectious Disease

References:

• Otoupalova E., et al. (2026). Aetiology of sepsis in adults living with HIV in East Africa: secondary analysis of open-label, multicentre, randomised, controlled phase 3 trial. The Lancet E-Clinical Medicine.
• ATLAS phase 3 trial results. The Lancet Infectious Disease.

Keywords:
Sepsis; HIV; Tuberculosis; Mycobacterium tuberculosis; East Africa; Infectious diseases; Clinical trial; ATLAS study; Sepsis mortality; Anti-tuberculosis therapy; Diagnostic challenges; HIV co-infection

The most vulnerable populations for these potential spikes include those in sub-Saharan Africa and marginalized groups already at an increased risk, such as sex workers, men who have sex with men, individuals who inject drugs, and children. This demographic targeting accentuates the severity and multiple layers of risk involved, as these groups often have limited access to necessary healthcare resources already. The anticipated cuts primarily stem from plans laid out by the top five global donor nations— the USA, the UK, France, Germany, and the Netherlands—which collectively contribute over 90% of international HIV funding. This impending reduction, projected to be around 24% by 2026, threatens to unravel years of progress made in the fight against HIV/AIDS.

The modelling approach utilized a comprehensive 26-country framework to gauge the potential effects of decreased international assistance. By simulating financial and epidemiological variables, the researchers were able to illustrate how a halt in foreign aid, particularly from the US President’s Emergency Plan for AIDS Relief (PEPFAR), would drastically undermine various HIV prevention and treatment programs already in place. This situation exemplifies a larger systemic issue—foreign aid has comprised nearly 40% of total funding for HIV initiatives in LMICs since 2015. Furthermore, with the US being responsible for approximately 73% of this funding, the ramifications of a funding cut from such a primary source would be sharply felt.

Since its inception, PEPFAR has offered a lifeline by providing vital treatment services, including antiretroviral therapy (ART) and HIV testing, alongside necessary laboratory services. However, cuts to PEPFAR funding threaten not just HIV-centric programs; they jeopardize broader healthcare provisions delivered by these initiatives. As funding for HIV-related services diminishes, health systems may also falter in their capacity to provide holistic, integrated care. For instance, during moments of reduced funding, associated health services like tuberculosis care and maternal health may experience equally damaging disruptions.

Dr. Debra ten Brink, co-lead author from the Burnet Institute in Australia, expressed grave concerns regarding the implications of these funding cuts. She emphasized that the United States has historically taken a leadership role in the international community’s battle against HIV/AIDS. However, the precision of current reductions threatens to impede access to essential healthcare services. Therefore, any further reduction in international financial support could put at risk the considerable advancements made in combating HIV over the past two decades.

The prospect of rising HIV cases and deaths due to diminished funding is stark. The authors of the study argue the pivotal role of strategic, long-term planning and collaboration on a global scale to salvage the progress made in HIV prevention and treatment. As sub-Saharan Africa stands at the frontline of HIV infection risks, it faces the possibility of reverting to higher prevalence rates, particularly concerning preventive measures such as condom distribution and health education programs, essential in combating the spread of HIV. When foundational prevention strategies are interrupted, the repercussions resonate through entire health systems, leading to increased incidence rates and, ultimately, a reversal of hard-won progress.

Additionally, the analysis highlighted that many countries receiving aid from PEPFAR have made considerable strides in reducing HIV-related infections and deaths. From 2010 to 2023, a significant annual decline in new HIV infections—averaging an 8.3% year-on-year drop and a 10.3% decline in related deaths—has marked this period. Yet, the continuation of this downward trend is now in jeopardy. The researchers indicated that without sustained foreign aid, countries could find themselves backtracking towards infection rates and mortality levels unseen since 2010, potentially undoing two decades of progress.

Beyond the immediate impacts of funding cuts, projections suggest that if interventions to restore support are eventually enacted after a prolonged absence, new HIV infection rates might stabilize but remain at levels similar to those observed in 2020. This scenario implies a profound long-term setback, potentially necessitating an additional 20 to 30 years of reinvestment to reclaim the advancements achieved in battling HIV/AIDS. The repercussions of inadequate funding are not merely health outcomes; they pose broader consequences for economic stability and public health infrastructure in affected regions.

Dr. Rowan Martin-Hughes, also from the Burnet Institute, underscored this urgent situation, noting that the halt of these crucial funding streams could upend significant preventive measures like the provision of pre-exposure prophylaxis (PrEP), thereby exacerbating the risk factors faced by already vulnerable communities. The swift action of donor countries is critical to avoid catastrophic rises in HIV infections and deaths, particularly in sub-Saharan Africa, where recent strides have demonstrated the possibility of substantial advancements.

The findings of this study cast a shadow on the optimistic trajectory many countries were poised to take towards meeting global goals aimed at eliminating HIV/AIDS as a public health threat by 2036. The authors concluded that a multi-pronged approach is essential—merging international support with domestic financial strategies is imperative for sustainability. Such integration would not only stabilize services for vulnerable populations but is crucial for the overarching mission to end the HIV epidemic globally.

As the global community grapples with these complex challenges, the authors also acknowledge limitations within their study. The unpredictable nature of foreign aid funding necessitates ongoing research and evaluation to provide accurate projections and responses to such concerning trends. A deeper understanding of budget optimization and prioritization strategies is also vital—these strategies could inform which interventions should take precedence in safeguarding against the resurgence of HIV infections on a global scale.

In conclusion, the findings of this pivotal modelling study serve as an urgent wake-up call regarding the ramifications of reduced international funding for HIV and AIDS programs. As the world remains in a precarious position, torn between fiscal conservatism and the moral imperative to assist those in dire need, the challenge to safeguard public health and advance human rights has never been stronger. The need for a coordinated global response, characterized by strategic planning and sustained investments in health systems, has never been more pressing.

Subject of Research: People
Article Title: Impact of an international HIV funding crisis on HIV infections and mortality in low-income and middle-income countries: a modelling study
News Publication Date: 26-Mar-2025
Web References: N/A
References: N/A
Image Credits: N/A
Keywords: HIV, AIDS, public health, foreign aid, funding cuts, modelling study, health systems, sub-Saharan Africa.

Enter Claire Najjuuko, a forward-thinking doctoral student at Washington University in St. Louis. During her work as a data manager at the International Center for Child Health and Development (ICHAD) in Uganda, she witnessed firsthand the challenges faced by adolescents struggling to adhere to ART. It was here that her passion for harnessing the power of artificial intelligence (AI) and machine learning to effect tangible health outcomes was ignited. Najjuuko’s research aims to understand and predict nonadherence to ART, which could lead to actionable interventions tailored specifically to the individuals most at risk.

In a groundbreaking effort published in the journal AIDS on February 25, 2025, Najjuuko and her collaborators—including the distinguished Professor Fred M. Ssewamala—embarked on a quest to develop a machine learning model to predict which adolescents are likely to struggle with keeping up with their HIV treatment. This initiative, supported by the AI for Health Institute, could revolutionize how healthcare systems in low-resource settings approach patient adherence. By identifying youths who are at high risk of nonadherence, healthcare practitioners can intervene more effectively, shifting the paradigm from reactive to proactive patient management.

The current methods largely depend on routine clinic visits every month or two, where healthcare providers assess adherence based on pill counts and discussions about missed doses. This traditional model, though foundational, falls short of addressing the complex factors influencing an adolescent’s willingness or ability to maintain their treatment regimen. Recognizing this, Najjuuko’s research holds the promise of integrating machine learning into these processes, dramatically altering the trajectory of adolescent health outcomes in Uganda and, potentially, beyond.

To train her predictive model, Najjuuko utilized data from a comprehensive six-year cluster-randomized controlled trial involving 39 clinics in southern Uganda, a region notably afflicted by HIV. The dataset, known as the Suubi+Adherence dataset, was rich with information gathered from adolescents who were medically diagnosed with HIV, aware of their condition, and enrolled in ART programs. This robust dataset ultimately included observations from 647 patients whose outcomes were tracked over 48 months, resulting in a formidable foundation for modeling nonadherence.

Through her analysis, Najjuuko incorporated an array of socio-behavioral and economic factors, layering these insights alongside each adolescent’s adherence history. Her findings are staggering; the model she developed was capable of identifying 80% of adolescents at risk for future nonadherence, while also lowering the rate of false alarms to 52%. Notably, this was a marked improvement of 14 percentage points over models that relied solely on adherence histories. Such accuracy is crucial in ensuring healthcare practitioners can efficiently allocate their resources where they are needed most.

Among the 50 distinct variables analyzed in the development of the model, certain characteristics emerged as particularly predictive of an individual’s adherence behavior. Economic factors were prominently linked to nonadherence, highlighting the significance of financial stability on health behaviors. Other determining characteristics included historical adherence to ART, socioeconomic status, the type of relationship adolescents had with their primary caregivers, levels of self-confidence, and educational enrollment. This multifaceted approach underscores the complexity of health behaviors, especially within adolescent populations navigating the burdens of poverty and stigma associated with HIV.

Ssewamala contextualizes this crisis by noting that adolescents represent one of the most nonadherent patient groups globally. The transition into independence often complicates their adherence commitments, compounded by social stigmas attached to their HIV status. As young individuals embark on the journey of romantic relationships and social interactions, the fear of being associated with HIV can deter them from openly discussing their health needs or accessing necessary treatments.

Interestingly, one of the factors that surfaced as positively associated with adherence was having a savings account. This finding resonates with the notion that financial security fosters a sense of optimism regarding the future, prompting more self-caring behaviors. As Ssewamala explains, individuals with financial resources are likelier to adopt responsible health behaviors as they foresee a future worth living for. Conversely, adolescents mired in hopelessness and poverty may feel they have little to lose, further hindering their commitment to treatment regimens.

The complexities of adhering to ART extend beyond mere personal accountability; environmental factors play a critical role. The requirement for medication to be taken with food or the potential for nausea poses significant challenges for those struggling with food insecurity or logistical barriers in accessing treatment. Adherence is not just a matter of willpower; it requires systemic support, and the healthcare infrastructure must adapt to meet these needs.

With Najjuuko’s model, there is hope for a revolution in how health practitioners engage with adolescents suffering from HIV. By arming healthcare providers with data-driven insights, they can tailor interventions more responsively, which is pivotal in a landscape where resources are often stretched thin. This innovative cross-disciplinary approach harnesses computational sciences to address deeply entrenched public health issues, demonstrating the immense potential at the intersection of technology and human health.

Professor Chenyang Lu emphasizes the collaborative nature of this groundbreaking research, which fuses artificial intelligence with global health initiatives. With extensive data amassed by Ssewamala’s team, Najjuuko’s work exemplifies the richness of interdisciplinary partnerships aimed at improving health outcomes. The nuanced understanding of complex health factors paves the way for analytical models that not only predict challenges but ultimately lead to enhanced service delivery for vulnerable populations.

In conclusion, Najjuuko’s ambitious project is a beacon of promise, indicating that innovative and data-driven methodologies can profoundly reshape the health landscape for adolescents grappling with HIV in Uganda. The synergy between AI, public health, and targeted intervention strategies heralds a new era of personalized healthcare that takes into account the intricate layers of individual experiences and systemic barriers. Through continued support and engagement in scientific research, there’s hope that we can shift the tide on youth adherence to ART, ensuring brighter futures for the millions affected by HIV.

Subject of Research: Machine Learning Predictive Model for Antiretroviral Therapy Adherence in Adolescents
Article Title: Using Machine Learning to Predict Poor Adherence to Antiretroviral Therapy Among Adolescents Living with HIV in Low-Resource Settings
News Publication Date: February 25, 2025
Web References: AIDS Journal
References: Najjuuko C, Brathwaite R, Xu Z, Kizito S, Lu C, Ssewamala FM.
Image Credits: N/A

Keywords: HIV, Adolescents, Machine Learning, Antiretroviral Therapy, Healthcare Interventions, Public Health, Predictive Modeling, Socioeconomic Factors